{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:54:12Z","timestamp":1788184452340,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CIRP-SYSUCC-0054"],"award-info":[{"award-number":["CIRP-SYSUCC-0054"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505800"],"award-info":[{"award-number":["2022YFC2505800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eclinm.2026.103893","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:48:14Z","timestamp":1776415694000},"page":"103893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study"],"prefix":"10.1016","volume":"95","author":[{"given":"FangJie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaQuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuangYu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaoTing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiMei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PengXin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"SiTu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengRu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DongSheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunYe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-6668","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2026.103893_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"10.1016\/j.eclinm.2026.103893_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103893_bib3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103893_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","article-title":"Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906)","volume":"81","author":"Kato","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103893_bib5","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.eclinm.2026.103893_bib6","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103893_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.eclinm.2026.103893_bib8","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumours","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103893_bib9","doi-asserted-by":"crossref","DOI":"10.4161\/onci.25962","article-title":"Enhancing immunotherapy using chemotherapy and radiation to modify the tumour microenvironment","volume":"2","author":"Kershaw","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.eclinm.2026.103893_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103184","article-title":"Safety and efficacy of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced esophageal squamous cell carcinoma in China (GASTO 1071): a non-randomised, two-cohort, phase 2 trial","volume":"82","author":"Liu","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103893_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65206-z","article-title":"Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial","volume":"16","author":"Peng","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.103893_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102471","article-title":"Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial","volume":"69","author":"Ai","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2026.103893_bib13","article-title":"Advances in hypofractionated irradiation-induced immunosuppression of tumour microenvironment","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103893_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijrobp.2018.01.094","article-title":"Abscopal effects with hypofractionated schedules extending into the effector phase of the tumour-specific T-cell response","volume":"101","author":"Zhang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"31","key":"10.1016\/j.eclinm.2026.103893_bib15","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103893_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7785\/tcrt.2012.500176","article-title":"Phase I\/II study of hypofractioned radiation with three-dimensional conformal radiotherapy for clinical T3-4N0-1M0 stage esophageal carcinoma","volume":"10","author":"Song","year":"2011","journal-title":"Technol Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.eclinm.2026.103893_bib17","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1158\/1078-0432.CCR-23-3600","article-title":"Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase I study","volume":"30","author":"Zhou","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103893_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijrobp.2023.04.021","article-title":"Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: results of A prospective phase II study (GASTO-1049)","volume":"117","author":"Zhou","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103893_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2026.103893_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radonc.2016.09.017","article-title":"Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumour responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma","volume":"121","author":"Qiu","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103893_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2004.06.022","article-title":"Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy","volume":"61","author":"Zhang","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103893_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-022-02127-x","article-title":"Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer","volume":"17","author":"Sridharan","year":"2022","journal-title":"Radiat Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103893_bib23","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103893_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"10.1016\/j.eclinm.2026.103893_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004591","article-title":"High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma","volume":"95","author":"Oh","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.eclinm.2026.103893_bib26","article-title":"Moderately hypo-fractionated radiotherapy combined with S-1 in inoperable locally advanced esophageal squamous cell carcinoma: a prospective, single-arm phase II study (GASTO-1045)","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103893_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103893_bib28","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/cam4.1250","article-title":"Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database","volume":"6","author":"Vlacich","year":"2017","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103893_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/0284186X.2018.1450521","article-title":"Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival","volume":"57","author":"Ko\u00ebter","year":"2018","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103893_bib30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clon.2019.01.010","article-title":"Hypofractionated radiotherapy in oesophageal cancer for patients unfit for systemic therapy: a retrospective single-centre analysis","volume":"31","author":"Jones","year":"2019","journal-title":"Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103893_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000492","article-title":"Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the ooesophagus","volume":"8","author":"Derby","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103893_bib32","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:39:20Z","timestamp":1781671160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026001410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S2589537026001410"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103893","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fraction dose escalation of split-course concurrent chemoradiotherapy following induction chemo-immunotherapy in unresectable locally advanced oesophageal squamous carcinoma in China (GASTO-10102): a single-centre phase 1 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103893"}}